Immune Checkpoint Biology in Health and Disease

Erscheinungsjahr 2024
ISBN: 978-0-443-13573-6
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 151 mm x 229 mm, Gewicht: 450 g

Immune Checkpoint Biology in Health and Disease, Volume 382 provides in-depth reviews on the latest progress concerning research on immune-checkpoint biology and its immunotherapeutic implications, especially in cancer. Topics connected to immune-checkpoint biology covered in this volume include Novel technologies for applying immune checkpoint blockers, Next-generation deconvolution of transcriptomic data to investigate the tumor microenvironment, Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer, Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients, and much more.

Other sections cover Recent advancements in tumor microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis, Immune Modulation During Anti-Cancer Radio(immuno)therapy, and Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy.

Autoren/Hrsg.

Weitere Mitwirkende

Garg, Abhishek

Fachgebiete

• Wirtschaftswissenschaften Volkswirtschaftslehre Volkswirtschaftslehre Allgemein Ökonometrie

Inhaltsverzeichnis

1. Novel technologies for applying immune checkpoint blockers
Robin Maximilian Awad, and Karine Breckpot
2. Next-generation deconvolution of transcriptomic data to investigate the tumor microenvironment
Lorenzo Merotto, Maria Zopoglou, Constantin Zackl, and Francesca Finotello
3. Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer
Xin Lei, Yizhi Wang, Chayenne Broens, Jannie Borst, and Yanling Xiao
4. Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients
Pierre Van Mol, Elena Donders, Diether Lambrechts, and Els Wauters
5. Recent advancements in tumour microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis
Madhavi Dipak Andhari, Asier Antoranz, Frederik De Smet, and Francesca Maria Bosisio
6. Immune Modulation During Anti-Cancer Radio(immuno)therapy
Teresa Irianto, Udo S. Gaipl, and Michael Rückert
7. Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy
Hui Pan, Peng Liu, Guido Kroemer, and Oliver Kepp

Über Autor(innen)

Garg, Abhishek
Prof. Abhishek D. Garg is currently Assistant Professor at Department of Cellular & Molecular Medicine (KU Leuven, Belgium) and head of the Laboratory for Cell Stress & Immunity also at KU Leuven. Dr. Garg did his post-doctoral training at KU Leuven, combined with research visitations at University of Helsinki, Finland, and De Duve Institute, Belgium, after receiving his PhD from KU Leuven. During his PhD-postdoc stints, Dr. Garg played an instrumental role in elucidating novel mechanisms that make cancer cell death immunogenic in the context of anticancer therapy. He worked on uncovering the links between endoplasmic reticulum stress, autophagy, apoptosis/necroptosis, and damage-associated molecular patterns (DAMPs) or danger signals in dying cancer cells. This work resulted in creation of innovative dendritic cell (DC) vaccines against glioblastoma.

His lab focuses on applying novel reverse translational approaches (i.e. human data to pre-clinical validation) to create innovative immunotherapy or biomarker solutions against hard-to-treat immunotherapy resistant tumors and eventually pave way for the forward translation of these solutions toward the clinic. His lab is working closely with oncologists (at home & abroad) for translation toward early-stage clinical trials.

His >100 publications have been cited >20,000 times (h-index >50). He has delivered >40 lectures at various (inter)national conferences or institutional/company seminars. Dr. Garg's contributions have been recognized by the 41st Prix Galien award for Pharmacological Research (Belgium, 2023), KU Leuven Research Council Award (2016), European Society of Photobiology (ESP) Young Investigator Award (2013), and FWO-McKinsey & Company Scientific Prize (2012).